The epidermal growth factor receptor as a novel target for cancer therapy: case studies and clinical implications.
To update the success and obstacles using therapies targeted to the epidermal growth factor receptor including IMC-C225, ZD1839, and OSI-774. Research articles, textbooks, clinical protocols, case studies. Ongoing studies show promise using monoclonal antibodies and small-molecule tyrosine kinase inhibitors in the treatment of non-small cell lung cancer and other malignancies. Such therapies can be delivered with limited toxicity to the host, and initial studies have shown single-agent efficacy and efficacy in combination with chemotherapy and/or radiation therapy. Nurses are directly involved in the delivery of these novel therapies and the management of associated toxicities. They serve to coordinate treatment protocols and help to ensure patient understanding and compliance.